A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

January 2, 2026

Study Completion Date

January 2, 2028

Conditions

Metastatic Appendiceal AdenocarcinomaIntraperitoneal Paclitaxel

Interventions

DRUG

Dexamethasone

Given by PO

DRUG

Diphenhydramine

Given by PO

DRUG

Famotidine

Given by PO

DRUG

Paclitaxel

Given by PO

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER